Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Teva
Deloitte
Healthtrust
Argus Health
Daiichi Sankyo
Moodys

Generated: April 24, 2018

DrugPatentWatch Database Preview

ADRIAMYCIN PFS Drug Profile

« Back to Dashboard

When do Adriamycin Pfs patents expire, and when can generic versions of Adriamycin Pfs launch?

Adriamycin Pfs is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in ADRIAMYCIN PFS is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
Drug patent expirations by year for ADRIAMYCIN PFS
Medical Subject Heading (MeSH) Categories for ADRIAMYCIN PFS
Synonyms for ADRIAMYCIN PFS
(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside hydrochloride
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride
(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hy
(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
(8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride
(8S,10S)-10-{[(2R,4S,5S,6S)-4-AMINO-5-HYDROXY-6-METHYLOXAN-2-YL]OXY}-6,8,11-TRIHYDROXY-8-(2-HYDROXYACETYL)-1-METHOXY-5,7,8,9,10,12-HEXAHYDROTETRACENE-5,12-DIONE HYDROCHLORIDE
10-[(3-Amino-2,3,6-trideoxy-?-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-5,12-naphthacenedione hydrochloride
139293-EP2270008A1
139293-EP2292617A1
23214-92-8 (Parent)
25316-40-9
316D409
33804-EP2275420A1
33804-EP2295055A2
33804-EP2295416A2
33804-EP2298748A2
33804-EP2298764A1
33804-EP2298765A1
33804-EP2305642A2
33804-EP2308833A2
33804-EP2311453A1
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)-
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)-
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, hydrochloride (8S-cis)-
82F2G7BL4E
AB0069925
AC1L9FFU
Adriacin
Adriacin (TN)
Adriamycin
Adriamycin (Doxorubicin Hydrochloride
Adriamycin (TN)
ADRIAMYCIN HYDROCHLORIDE
Adriamycin hydrochloride-DNA complex
Adriamycin RDF
ADRIAMYCIN, HYDROCHLORIDE
Adriblastin
Adriblastina
Adriblastina hydrochloride
Adrosal
AKOS007930231
AKOS015920241
AOB5216
BCP9000237
BCPP000429
BID0120
Bio-0029
BR-72874
Caelyx
CAS-25316-40-9
CAS-NOCAS_45111
CCG-100975
CCRIS 740
CD0186
CHEBI:31522
CHEMBL359744
CPD000058570
CS-1239
D01275
D0F4KU
DOX
DOX base
Doxil (TN)
Doxorubicin (Adriamycin) HCl
Doxorubicin (hydrochloride)
Doxorubicin HCl
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (JP17/USP)
Doxorubicin hydrochloride [USP:JAN]
Doxorubicin hydrochloride solution
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Doxorubicin Hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
Doxorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Doxorubicin, free base
doxorubicin.HCl
DSSTox_CID_10636
DSSTox_GSID_30636
DSSTox_GSID_45111
DSSTox_RID_78854
DSSTox_RID_80678
DTXSID3030636
Duxocin
EINECS 246-818-3
EX-A1337
FT-0082477
HMS1569G18
HY-15142
Hydroxydaunorubicin hydrochloride
KSC-230-184-1
KUC110341C
KW-125
Lipo-Dox
Lipodox
MCULE-5540454667
MFCD00077757
MLS000028393
MLS000049969
MLS000049970
MLS000049971
MLS000070047
MLS000392861
MLS000392871
MLS000392881
MLS000392891
MLS000392901
MLS000759533
MLS001055359
MLS001401460
MolPort-003-933-100
MWWSFMDVAYGXBV-RUELKSSGSA-N
NC00225
NCGC00014486-01
NCGC00024415-33
NCGC00024415-36
NCGC00163543-01
NCGC00260032-01
NCGC00263918-03
NSC 123127
NSC-123127
PL010839
Prestwick_188
RL02839
Rubex
Rubex (TN)
s1208
SAM001246768
SCHEMBL3242
SMR000058570
SR-01000003049
SR-01000003049-10
ST2419270
Tox21_110050
Tox21_110050_1
Tox21_112061
Tox21_202483
UNII-82F2G7BL4E
W-5070
Z1557399790
ZX-AFC000216

US Patents and Regulatory Information for ADRIAMYCIN PFS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn ADRIAMYCIN PFS doxorubicin hydrochloride INJECTABLE;INJECTION 063165-001 Jan 30, 1991 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pharmacia And Upjohn ADRIAMYCIN PFS doxorubicin hydrochloride INJECTABLE;INJECTION 063165-002 Jan 30, 1991 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
Healthtrust
Boehringer Ingelheim
Harvard Business School
Cerilliant
Colorcon
McKinsey
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.